Portola Pharmaceuticals Inc (NASDAQ:PTLA) has been assigned a consensus recommendation of “Hold” from the eleven ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $38.75.
Several brokerages have recently issued reports on PTLA. Zacks Investment Research upgraded shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research report on Wednesday, October 9th. Credit Suisse Group restated a “neutral” rating and set a $35.00 price target on shares of Portola Pharmaceuticals in a research report on Monday, August 5th. BidaskClub raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Citigroup decreased their price target on shares of Portola Pharmaceuticals from $51.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. Finally, Goldman Sachs Group started coverage on Portola Pharmaceuticals in a report on Friday, November 8th. They issued a “neutral” rating and a $35.00 price objective on the stock.
Shares of NASDAQ:PTLA traded up $0.11 during midday trading on Tuesday, reaching $27.79. 1,142,217 shares of the company’s stock traded hands, compared to its average volume of 807,596. The company has a fifty day simple moving average of $28.51 and a two-hundred day simple moving average of $28.04. Portola Pharmaceuticals has a 1 year low of $14.81 and a 1 year high of $37.95. The company has a market cap of $2.16 billion, a P/E ratio of -5.55 and a beta of 2.07. The company has a debt-to-equity ratio of 1.25, a quick ratio of 5.85 and a current ratio of 5.88.
In other Portola Pharmaceuticals news, Director Hollings Renton sold 5,000 shares of Portola Pharmaceuticals stock in a transaction on Friday, November 1st. The shares were sold at an average price of $30.00, for a total transaction of $150,000.00. Following the sale, the director now owns 18,194 shares of the company’s stock, valued at approximately $545,820. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 4.50% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of PTLA. Parametric Portfolio Associates LLC lifted its stake in shares of Portola Pharmaceuticals by 14.8% in the second quarter. Parametric Portfolio Associates LLC now owns 78,006 shares of the biopharmaceutical company’s stock worth $2,116,000 after buying an additional 10,065 shares in the last quarter. Oppenheimer & Co. Inc. raised its holdings in Portola Pharmaceuticals by 1.7% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 22,916 shares of the biopharmaceutical company’s stock valued at $614,000 after acquiring an additional 393 shares during the last quarter. First Trust Advisors LP purchased a new position in Portola Pharmaceuticals in the 2nd quarter worth approximately $3,110,000. Emerald Advisers LLC lifted its stake in Portola Pharmaceuticals by 32.5% in the 2nd quarter. Emerald Advisers LLC now owns 536,870 shares of the biopharmaceutical company’s stock worth $14,565,000 after purchasing an additional 131,750 shares in the last quarter. Finally, Family Management Corp acquired a new position in shares of Portola Pharmaceuticals during the 2nd quarter worth approximately $529,000.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Further Reading: CBOE Russell 2000® Volatility Index
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.